精彩前沿，不容錯(cuò)過(guò)
 

隨著技術(shù)不斷進(jìn)步，當(dāng)前生命科學(xué)基礎(chǔ)研究和新藥研發(fā)都得到了飛速發(fā)展。特別是在新藥研發(fā)領(lǐng)域，不僅生物大分子藥已開始大行其道，小分子藥物也隨著PROTAC的出現(xiàn)掀起了小分子藥物研發(fā)的新浪潮。當(dāng)前的新藥研發(fā)對(duì)于高通量，快速和精準(zhǔn)的分析方案有著迫切的需求。如何在快速發(fā)展，激烈競(jìng)爭(zhēng)的創(chuàng)新藥研發(fā)過(guò)程中，加速提質(zhì)創(chuàng)新，提升藥物研發(fā)的成功率，已成為當(dāng)前最引人注目的焦點(diǎn)。

此次網(wǎng)絡(luò)論壇，誠(chéng)邀國(guó)際多位行業(yè)專家，共話創(chuàng)新，分享討論高通量藥物篩選前沿技術(shù)最新動(dòng)態(tài)趨勢(shì)。

受邀出席專家來(lái)自
>>德國(guó)BMG LABTECH公司—專注高通量藥篩領(lǐng)域的多功能酶標(biāo)儀廠家
>>瑞士Creoptix公司—創(chuàng)新研發(fā)出GCI超靈敏超快速分析無(wú)標(biāo)記分子相互作用的廠家
>>英國(guó)Domainex公司—對(duì)難靶向酶開發(fā)極具經(jīng)驗(yàn)的CRO  

在此，我們誠(chéng)邀您報(bào)名參與，希望借此機(jī)會(huì)與您及業(yè)內(nèi)專家們，一起追蹤動(dòng)態(tài)趨勢(shì)，討論前沿方案，助力新藥研發(fā)。

會(huì)議時(shí)間
2022年01月12日 16:00-18:00

參會(huì)方式

長(zhǎng)按或掃描以下二維碼填表報(bào)名

主講人簡(jiǎn)介

Ann-Cathrin Volz works as Application Specialist for BMG LABTECH with specific focus on cell-based assays. After her graduation in Nutritional Sciences at the University of Hohenheim she completed her PhD and a Postdoc in the field of Tissue Engineering. In her position, she can draw on her experience in cell culture and related microplate-based assays to support customers in assay optimisation for existing and emerging applications.
 

Also part of BMG´s Application Specialist team, Martin Mangold focusses on enzyme-based assays. He graduated in biology followed by a Master of Science in the field of drug research. He went on and completed his PhD in the field of medicinal chemistry at the University of Bonn. Now he uses his knowledge of enzyme-based and drug screening microplate assays to support customers with their applications and assay optimisation.
 

Tatiana Tiago is the Product Manager at Creoptix with over 8 years’ experience in pharma and biotech industry. Her background in molecular biology has given her a wide understanding of binding interaction analysis including label-based and label-free technologies. Tatiana holds a degree in in Medical Molecular Biology from the University of Westminster and a PhD in Neuroscience from the University of Modena and Reggio Emilia. Recently, Tatiana’s focus is to help life-science scientist understand GCI and optimize the label-free WAVEsystem enabling them to accelerate drug discovery.
 

Trevor Askwith is a cell biologist and biochemist with over 10 years’ experience of small-molecule drug discovery research. He began is drug discovery career as a cell biologist at Novartis where and has more recently worked in academic drug discovery running leading the Assay Development and Screening in the Drug Discovery Group at UCL. Trevor is now the Group Leader for Assay Biology a Domainex responsible of the biophysics, biochemistry and cell biology departments.
 

Dr Tom Mander has nearly 30 years of small molecule drug discovery and translational research experience in both scientific and commercial roles. After graduating and working at Amersham International plc developing radioimmunoassays, he completed his DPhil studies with Professor John Morris into the roles of microglial cells at the Department of Human Anatomy, University of Oxford in 1992. Tom joined Domainex in April 2015 as Chief Operating Officer to oversee the scientific service operations and business development activities of the company. During his time in this role, he has established a broad portfolio of pharma, biotech, academic and patient foundation clients both in the UK and overseas, launched several new services and has overseen the growth of the company. In April 2020, he took over as Chief Executive Officer after the retirement of Dr  Trevor Perrior

BMG LABTECH為德國(guó)多功能酶標(biāo)儀制造商，多年來(lái)專注研發(fā)酶標(biāo)儀技術(shù)，特別是為科研單位，藥企和CRO的高通量藥篩應(yīng)用帶來(lái)強(qiáng)大的優(yōu)勢(shì)。BMG高端PHERAstar系統(tǒng)在藥篩領(lǐng)域近年更是受到諸多認(rèn)可。

瑞士Creoptix，擁有基于光柵耦合干涉技術(shù)（Grating-Coupled Interferometry ，GCI）的光學(xué)生物傳感器專利，以及外置的微流體的獨(dú)特設(shè)計(jì)和Google公司研發(fā)的自動(dòng)化軟件。致力于提供高質(zhì)量的動(dòng)力學(xué)數(shù)據(jù)，擁有業(yè)內(nèi)最靈敏準(zhǔn)確的WAVEsystem無(wú)標(biāo)記分子相互作用儀，使全球生物科學(xué)研究者可以做以前不可能做的事情，看到以前看不見(jiàn)的數(shù)據(jù)。憑借突破性的創(chuàng)新，避開了SPR的局限性，突破無(wú)標(biāo)記技術(shù)的局限。

Domainex是一家英國(guó)老牌綜合性藥物發(fā)現(xiàn)服務(wù)公司，針對(duì)難靶向的酶開發(fā)一流。

歡迎關(guān)注伯齊官方微信（微信公眾號(hào)：Bio-Gene）

回復(fù)：BMG，查看相關(guān)視頻

長(zhǎng)按以下二維碼可識(shí)別關(guān)注公眾號(hào)

伯齊科技有限公司

Bio-Gene Technology Ltd.

廣州伯齊生物科技有限公司

熱線：176 2009 3784

www.bio-gene.com.cn

marketing@bio-gene.com.cn

香港 北京 上海 廣州 成都 武漢 濟(jì)南